Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2141-V11 + Nivolumab + 5-FU in Advanced Gastroesophageal Adenocarcinoma
NCT07818018Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 2 trial of 2141-V11 in esophageal adenocarcinoma (EAC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2026; status: recruiting.
02
Drugs
2141-V11
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07818018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818018.